Who Owns AngioDynamics Company?

AngioDynamics Bundle

Get Full Bundle:

	5 FORCES	$15	$10
	BCG	$15	$10
	CANVAS	$15	$10
	4P's MIX	$15	$10
	PESTLE	$15	$10
	SWOT	$15	$10

TOTAL:

ADD TO CART

Who owns AngioDynamics now?

After the June 2024 divestiture of PICC and ports to Boston Scientific for $160,000,000, investor attention turned to who controls AngioDynamics’ strategy and board decisions. Ownership is dispersed across founders, insiders, institutions, and index funds.

AngioDynamics, Inc. (NASDAQ: ANGO), founded 1988, is a small-cap medtech firm with market cap typically between $300,000,000 and $500,000,000 in 2024–2025 and no single controlling shareholder.

See strategic context in AngioDynamics Porter's Five Forces Analysis

Founders and Early Ownership of AngioDynamics began in 1988 when Eamonn P. Hobbs launched the company with engineering and clinical collaborators from upstate New York’s medtech community; early ownership was dominated by a corporate parent rather than traditional venture capital backing.

Founder and Ecosystem

Eamonn P. Hobbs led technical founders and clinicians from the regional medtech cluster to form the business in 1988.

Parent Company Backing

Early capital and ownership were provided by E-Z-EM, Inc., which acted as principal owner and financier rather than venture investors.

Equity Structure

Founder-management received options and restricted stock with time-based vesting; exact initial splits were not publicly disclosed.

Compensation Design

Early executive pay emphasized incentive ownership: option pools, repurchase rights, and standard buy-sell provisions on departure.

Dilution Ahead of IPO

As AngioDynamics scaled toward public listing, founder stakes were diluted by employee option pools and continued parent holdings.

Governance and Control

Early control reflected E-Z-EM’s strategic intent to expand vascular access and interventional radiology offerings; no material founder litigation appears in SEC records.

Corporate-parent-led seed funding meant friends-and-family or angel rounds are not recorded; public filings and SEC disclosures later show increasing institutional owners and dilution of early insider percentages as the company transitioned to public markets.

Key Early Ownership Facts

Founding, financing and equity arrangements that shaped initial control and incentives.

• Eamonn P. Hobbs identified as founder in historical records from 1988.
• E-Z-EM, Inc. served as principal owner and financier during inception and early growth.
• Founder compensation primarily option-based with standard repurchase and vesting terms.
• Specific inception equity splits among founders were not publicly disclosed in filings.

Further context on AngioDynamics ownership evolution and shareholder composition can be found in the company’s filings and in this overview of its market approach: Marketing Strategy of AngioDynamics

AngioDynamics SWOT Analysis

• Complete SWOT Breakdown
• Fully Customizable
• Editable in Excel & Word
• Professional Formatting
• Investor-Ready Format

GET TEMPLATE ➔

Key events shaping AngioDynamics ownership include the 2004 IPO, strategic acquisitions (RITA Medical 2006; Navilyst 2012), progressive institutionalization of the float, and portfolio pruning including the 2024 sale of the PICC/ports business to Boston Scientific, which concentrated investor focus on higher‑margin franchises.

Current register shows a broad public float dominated by passive/index funds and healthcare‑focused active managers; insiders (executives and directors) typically hold low single‑digit percentages via RSUs/PSUs/options, and no controlling shareholder exists.

Ownership snapshot and governance signals

Institutional and index ownership are the largest blocks; Vanguard and BlackRock commonly rank among the top holders, each often in the mid‑to‑high single digits, while active healthcare funds hold dispersed sub‑10% stakes.

• 2004 IPO set public float with ~2.8M shares at $12 per share
• Aggregate institutional ownership around 75%–90% for small‑cap medtech peers; AngioDynamics near higher end
• Insider ownership generally in the low single digits (executives + board)
• 2024 strategic divestiture (PICC/ports) shifted investor focus to Auryon and NanoKnife IRE

For context on company origins and earlier ownership history see Brief History of AngioDynamics.

AngioDynamics PESTLE Analysis

• Covers All 6 PESTLE Categories
• No Research Needed – Save Hours of Work
• Built by Experts, Trusted by Consultants
• Instant Download, Ready to Use
• 100% Editable, Fully Customizable

GET TEMPLATE ➔

The AngioDynamics board (2024–2025) is led by a mix of independent directors with medtech, finance and commercialization experience alongside the CEO; the board oversees Audit, Compensation and Nominating/Corporate Governance committees and reflects a dispersed ownership base without a controlling shareholder.

Voting follows a one-share-one-vote structure with a single class of common stock; there are no dual-class or golden-share provisions and no disclosed board seats reserved for any investor.

Board & Voting Snapshot

The board is majority independent; standard committees monitor finance, pay and governance. Institutional investors and proxy advisers drive key vote outcomes.

• Voting: one-share-one-vote, single common class
• Board: predominantly independent with CEO as director
• Committees: Audit, Compensation, Nominating/Corporate Governance
• Proxy dynamics influenced by top index funds and active managers

Shareholder engagement through 2024–2025 has focused on portfolio optimization, R&D prioritization (notably NanoKnife and Auryon), operating discipline and say-on-pay scrutiny; recent proxy votes and director elections have generally passed with typical institutional majorities, reflecting dispersed ownership and no majority holder—see Revenue Streams & Business Model of AngioDynamics for related company context.

AngioDynamics Business Model Canvas

• Complete 9-Block Business Model Canvas
• Effortlessly Communicate Your Business Strategy
• Investor-Ready BMC Format
• 100% Editable and Customizable
• Clear and Structured Layout

GET TEMPLATE ➔

Since 2019 AngioDynamics ownership shifted toward institutional and passive holders as the company refocused on peripheral vascular and oncology, with insiders holding modest stakes due to equity compensation and ongoing issuances; a June 2024 divestiture to Boston Scientific further reshaped investor interest toward higher-margin, growth segments.

Institutional and passive holders now represent a large share of AngioDynamics shareholders, analysts note possible activist interest given sub‑scale market cap and SOTP optionality, while management has signaled no near‑term recapitalization or voting‑structure change.

Capital allocation

Management prioritized debt paydown and growth investment after the $160 million divestiture, limiting large buybacks and keeping leverage and liquidity targets central to strategy.

Institutional profile

Index funds and healthcare sector ETFs increased exposure; major institutional holders comprise the largest block but no single majority owner exists through mid‑2025.

Regulatory and clinical drivers

Ownership sentiment is tied to NanoKnife (IRE) regulatory milestones and Auryon commercial scaling; these clinical readouts drive valuation and M&A optionality.

M&A and takeover potential

Analysts cite bolt‑on acquisition upside or potential target status if growth inflects; activist screening remains plausible given sum‑of‑the‑parts value.

For more context on market positioning and the company’s product focus affecting who owns AngioDynamics, see Target Market of AngioDynamics.

AngioDynamics Porter's Five Forces Analysis

• Covers All 5 Competitive Forces in Detail
• Structured for Consultants, Students, and Founders
• 100% Editable in Microsoft Word & Excel
• Instant Digital Download – Use Immediately
• Compatible with Mac & PC – Fully Unlocked

GET TEMPLATE ➔